Gingival Cell Growth with Antiresorptive Treatment Combined with Corticosteroids or Antiestrogen

Overview

Journal Clin Exp Dent Res

Publisher Wiley

Specialty Dentistry

Date 2021 Jan 14

PMID 33443783

Citations 2

Authors

Heidi M Ekholm

Eliisa Loyttyniemi

Tero Soukka

Jaana Rautava

Affiliations

Soon will be listed here.

Abstract

Objectives: Antiresorptive treatment has been shown to impair mucosal cell proliferation, migration, and viability. However, in the clinic, antiresorptives are often used in combination with other drugs. We studied the effect of antiresorptives combined with a corticosteroid or antiestrogen on oral mucosal keratinocytes and fibroblasts.

Material And Methods: Human gingival keratinocyte and fibroblast cell lines were exposed to bisphosphonates (BPs) and denosumab in different concentrations and durations together with an antiestrogen or corticosteroid. Changes in cell viability, proliferation and migration after exposures were measured. Data were evaluated with hierarchical linear mixed model for repeated measurements.

Results: Bisphosphonate exposure suppressed keratinocyte and fibroblast cell viability, proliferation, and migration in a time-dependent manner. Combining a corticosteroid or antiestrogen with BPs further increased this negative effect. Denosumab alone had a mild positive effect on keratinocyte and fibroblast growth. When denosumab was combined with a corticosteroid or antiestrogen, cell growth was suppressed.

Conclusions: Our results show that coexisting medications may increase the negative impact of BPs or denosumab on oral mucosal cells.

Citing Articles

Assessment of the occurrence of apical periodontitis and endodontically treated/non-treated teeth in a Lower Austrian patient population treated for osteoporosis: a cohort study.

Grun P, Meier M, Dittrich J, Gjergjindreaj A, Strobele D, Pfaffeneder-Mantai F Ann Med Surg (Lond). 2024; 86(9):5049-5057.

PMID: 39239028 PMC: 11374243. DOI: 10.1097/MS9.0000000000002443.

Gingival cell growth with antiresorptive treatment combined with corticosteroids or antiestrogen.

Ekholm H, Loyttyniemi E, Soukka T, Rautava J Clin Exp Dent Res. 2021; 7(4):465-473.

PMID: 33443783 PMC: 8404500. DOI: 10.1002/cre2.382.

References

Baron R, Ferrari S, Russell R . Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2010; 48(4):677-92. DOI: 10.1016/j.bone.2010.11.020. View

Ruggiero S, Dodson T, Fantasia J, Goodday R, Aghaloo T, Mehrotra B . American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014; 72(10):1938-56. DOI: 10.1016/j.joms.2014.04.031. View

Ruutu M, Rautava J, Turunen A, Tirri T, Syrjanen S . 17β-estradiol and progesterone effect on human papillomavirus 16 positive cells grown as spheroid co-cultures. Cytotechnology. 2017; 70(1):235-244. PMC: 5809654. DOI: 10.1007/s10616-017-0137-9. View

Chiu C, Chiang W, Chuang C, Chang S . Resolution of oral bisphosphonate and steroid-related osteonecrosis of the jaw--a serial case analysis. J Oral Maxillofac Surg. 2010; 68(5):1055-63. DOI: 10.1016/j.joms.2009.12.030. View

Giannopoulou C, Martinelli-Klay C, Lombardi T . Immunohistochemical expression of RANKL, RANK and OPG in gingival tissue of patients with periodontitis. Acta Odontol Scand. 2012; 70(6):629-34. DOI: 10.3109/00016357.2011.645064. View

Walter C, Pabst A, Ziebart T, Klein M, Al-Nawas B . Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro. Oral Dis. 2010; 17(2):194-9. DOI: 10.1111/j.1601-0825.2010.01720.x. View

Oteri G, Campisi G, Panzarella V, Morreale I, Nucera R, Di Fede O . Could the Combined Administration of Bone Antiresorptive Drug, Taxanes, and Corticosteroids Worsen Medication Related Osteonecrosis of the Jaws in Cancer Patients?. Biomed Res Int. 2018; 2018:4021952. PMC: 5996467. DOI: 10.1155/2018/4021952. View

Basso F, Pansani T, Oliveira C, Turrioni A, Soares D, Hebling J . Cytotoxic effects of zoledronic acid on human epithelial cells and gingival fibroblasts. Braz Dent J. 2014; 24(6):551-8. DOI: 10.1590/0103-6440201302229. View

Robertson J, Odling-Smee W, Holcombe C, Kohlhardt S, Harrison M . Pharmacokinetics of a single dose of fulvestrant prolonged-release intramuscular injection in postmenopausal women awaiting surgery for primary breast cancer. Clin Ther. 2003; 25(5):1440-52. DOI: 10.1016/s0149-2918(03)80131-5. View

10.

Usui M, Sato T, Yamamoto G, Okamatsu Y, Hanatani T, Moritani Y . Gingival epithelial cells support osteoclastogenesis by producing receptor activator of nuclear factor kappa B ligand via protein kinase A signaling. J Periodontal Res. 2015; 51(4):462-70. DOI: 10.1111/jre.12323. View

11.

Hagelauer N, Ziebart T, Pabst A, Walter C . Bisphosphonates inhibit cell functions of HUVECs, fibroblasts and osteogenic cells via inhibition of protein geranylgeranylation. Clin Oral Investig. 2014; 19(5):1079-91. DOI: 10.1007/s00784-014-1320-4. View

12.

McLeod N, Moutasim K, Brennan P, Thomas G, Jenei V . In vitro effect of bisphosphonates on oral keratinocytes and fibroblasts. J Oral Maxillofac Surg. 2013; 72(3):503-9. DOI: 10.1016/j.joms.2013.08.007. View

13.

Otto S, Schreyer C, Hafner S, Mast G, Ehrenfeld M, Sturzenbaum S . Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment. J Craniomaxillofac Surg. 2011; 40(4):303-9. DOI: 10.1016/j.jcms.2011.05.003. View

14.

Pabst A, Ziebart T, Koch F, Taylor K, Al-Nawas B, Walter C . The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes--in vitro study. Clin Oral Investig. 2011; 16(1):87-93. DOI: 10.1007/s00784-010-0507-6. View

15.

de Boissieu P, Gaboriau L, Morel A, Trenque T . Bisphosphonate-related osteonecrosis of the jaw: data from the French national pharmacovigilance database. Fundam Clin Pharmacol. 2016; 30(5):450-8. DOI: 10.1111/fcp.12211. View

16.

McGowan K, McGowan T, Ivanovski S . Risk factors for medication-related osteonecrosis of the jaws: A systematic review. Oral Dis. 2017; 24(4):527-536. DOI: 10.1111/odi.12708. View

17.

Ravosa M, Ning J, Liu Y, Stack M . Bisphosphonate effects on the behaviour of oral epithelial cells and oral fibroblasts. Arch Oral Biol. 2010; 56(5):491-8. DOI: 10.1016/j.archoralbio.2010.11.003. View

18.

Acil Y, Moller B, Niehoff P, Rachko K, Gassling V, Wiltfang J . The cytotoxic effects of three different bisphosphonates in-vitro on human gingival fibroblasts, osteoblasts and osteogenic sarcoma cells. J Craniomaxillofac Surg. 2011; 40(8):e229-35. DOI: 10.1016/j.jcms.2011.10.024. View

19.

Scheper M, Badros A, Salama A, Warburton G, Cullen K, Weikel D . A novel bioassay model to determine clinically significant bisphosphonate levels. Support Care Cancer. 2009; 17(12):1553-7. DOI: 10.1007/s00520-009-0710-7. View

20.

Reid I, Bolland M, Grey A . Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?. Bone. 2007; 41(3):318-20. DOI: 10.1016/j.bone.2007.04.196. View